OnCo
companiesCompany

Nurix Therapeutics

Nurix Therapeutics is developing bexobrutideg, a brain-penetrant BTK degrader in pivotal trials for CLL, co-developed with Roche from June 2026.

Bexobrutideg (NX-5948) degrades wild-type and inhibitor-resistant BTK; durable responses in relapsed/refractory CLL/SLL (EHA 2026 oral). 2026 plan: DAYBreak CLL-201 phase 2 and a confirmatory phase 3. Roche global co-development and co-commercialisation deal announced June 2026 (HSR cleared July).

Headquarters
San Francisco, CA, US
Type
biotech · NRIX

Connected

12top

cancers

2
Chronic lymphocytic leukaemiaDiffuse large B-cell lymphoma

fronts

1
Targeted Therapy

technologies

2
Molecular glue discovery platformsPROTACs & molecular glues (targeted protein degradation)

companies

1
Roche / Genentech

ideas

4
Design protein degraders small enough to get into the brainFind E3 ligases that only tumours have, and build degraders around themScreen glue-like compounds against every cancer cell line and publish itUse antibodies to deliver protein-destroying drugs into the right cells

bottlenecks

2
Acquired resistance to every therapyThe undruggable drivers